MARIA BEGOÑA
VILLAR CHEDA
Senior university lecturer
![Foto de MARIA BEGOÑA](/img/nophoto.png)
![Foto de Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas](/img/noimage_org.png)
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas
Madrid, EspañaPublications in collaboration with researchers from Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (20)
2024
-
Angiotensin type 1 receptor activation promotes neuronal and glial alpha-synuclein aggregation and transmission
npj Parkinson's Disease, Vol. 10, Núm. 1
2022
2021
-
Nadph-oxidase, rho-kinase and autophagy mediate the (Pro)renin-induced pro-inflammatory microglial response and enhancement of dopaminergic neuron death
Antioxidants, Vol. 10, Núm. 9
-
The intracellular renin-angiotensin system: Friend or foe. Some light from the dopaminergic neurons
Progress in Neurobiology, Vol. 199
2018
-
Paracrine and Intracrine Angiotensin 1-7/Mas Receptor Axis in the Substantia Nigra of Rodents, Monkeys, and Humans
Molecular Neurobiology, Vol. 55, Núm. 7, pp. 5847-5867
2017
-
Insulin-like growth factor-1 and neuroinflammation
Frontiers in Aging Neuroscience
-
The intracellular angiotensin system buffers deleterious effects of the extracellular paracrine system
Cell death & disease, Vol. 8, Núm. 9, pp. e3044
2016
-
Aging-related Increase in Rho Kinase Activity in the Nigral Region is Counteracted by Physical Exercise
Journals of Gerontology - Series A Biological Sciences and Medical Sciences, Vol. 71, Núm. 10, pp. 1254-1257
-
Mitochondrial angiotensin receptors in dopaminergic neurons. Role in cell protection and aging-related vulnerability to neurodegeneration
Cell Death and Disease, Vol. 7, Núm. 10
2015
-
Rho Kinase and Dopaminergic Degeneration: A Promising Therapeutic Target for Parkinsons Disease
Neuroscientist, Vol. 21, Núm. 6, pp. 616-629
2014
-
Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with l-DOPA
Neuropharmacology, Vol. 76, Núm. PART A, pp. 156-168
-
Inhibition of the microglial response is essential for the neuroprotective effects of Rho-kinase inhibitors on MPTP-induced dopaminergic cell death
Neuropharmacology, Vol. 85, pp. 1-8
2013
-
Dopamine-Angiotensin interactions in the basal ganglia and their relevance for Parkinson's disease
Movement Disorders, Vol. 28, Núm. 10, pp. 1337-1342
-
Expression of angiotensinogen and receptors for angiotensin and prorenin in the monkey and human substantia nigra: An intracellular renin-angiotensin system in the nigra
Brain Structure and Function, Vol. 218, Núm. 2, pp. 373-388
2012
-
Aging-related changes in the nigral angiotensin system enhances proinflammatory and pro-oxidative markers and 6-OHDA-induced dopaminergic degeneration
Neurobiology of Aging, Vol. 33, Núm. 1, pp. 204.e1-204.e11
-
Brain angiotensin and dopaminergic degeneration: Relevance to Parkinson’s disease
American Journal of Neurodegenerative Diseases, Vol. 1, Núm. 3, pp. 226-244
-
Involvement of microglial RhoA/Rho-Kinase pathway activation in the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors
Neurobiology of Disease, Vol. 47, Núm. 2, pp. 268-279
2011
-
Aging, angiotensin system and dopaminergic degeneration in the substantia nigra
Aging and Disease, Vol. 2, Núm. 3, pp. 257-274
2010
-
Nigral and striatal regulation of angiotensin receptor expression by dopamine and angiotensin in rodents: Implications for progression of Parkinson's disease
European Journal of Neuroscience, Vol. 32, Núm. 10, pp. 1695-1706
2009
-
Aging and sedentarism decrease vascularization and VEGF levels in the rat substantia nigra. Implications for Parkinson's disease
Journal of Cerebral Blood Flow and Metabolism, Vol. 29, Núm. 2, pp. 230-234